FDA nod for GSK’s Blujepa for UTIs

Pharma major GSK (LSE: GSK) on Tuesday said its urinary tract infection treatment gepotidacin, under the brand name Blujepa, has been approved in the USA.

The London-based company said the US Food and Drug Administration has approved Blujepa for the treatment of uncomplicated UTIs in female adults and paediatric patients 12 years of age and older.
Discovered by GSK scientists, Blujepa is a first-in-class oral antibiotic with a novel mechanism of action that is part of GSK’s infectious diseases portfolio, the company noted.

Tony Wood, chief scientific officer, GSK, said: “The approval of Blujepa is a crucial milestone with uUTIs among the most common infections in women. We are proud to have developed Blujepa, the first in a new class of oral antibiotics for uUTIs in nearly three decades, and to bring another option to patients given recurrent infections and rising rates of resistance to existing treatments.”
Blujepa, which is expected to launch in the USA in the second half of this year, is one of five new product launches anticipated from GSK this year - which could help lift the company’s bottom line as it seeing slipping vaccine sales.